Navigation Links
Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/5/2007

- Company Will Present Seven Posters and sponsor Satellite Symposium at Key

Scientific Gathering at McCormick Place in Chicago, September 17

- 20 -

CHICAGO, Sept. 5 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), will present seven posters on selected cethromycin therapeutic studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) at McCormick Place in Chicago, September 17 - 20. ICAAC, a key scientific event expected to attract more than 12,000 scientists from around the world, is a gathering of leading researchers and clinicians to discuss important themes and present the newest treatment advances in infectious disease. The Advanced Life Sciences booth, #643, will be located in Hall D in the Lakeside Center at McCormick Place.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO)

The Advanced Life Sciences poster presentations will discuss in vitro activity of cethromycin against key susceptible and resistant pathogens involved in community acquired pneumonia (CAP) as well as safety data in certain special clinical populations. Along with collaborators such as the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Eurofins Medinet, Micromyx and Battelle, the Company will present data demonstrating the potency of cethromycin against pathogens involved in bioterrorism.

In addition, Advanced Life Sciences is sponsoring a satellite symposium entitled "Drug Resistant CAP, Current and Future Treatments: Best Practices for Prevention and Management". The panel, moderated by Gerald Donowitz, M.D., will feature presentations by Richard Wunderink, M.D., Joseph Blondeau, Ph.D. and B. Joseph Guglielmo, Jr., Pharm.D., all thought leaders in the field of infectious disease and microbiology. The satellite symposium is supported by Advanced Life Sciences through an unrestricted educational grant to the American Society for Microbiology and Conexus Health.

Symposium and Presentation Schedule

Monday, September 17, 7:00 p.m. Central Daylight Time, Room E354A

-- Satellite Symposium: Drug Resistant CAP, Current and Future Treatments:

Best Practices for Prevention and Management

Tuesday, September 18, 11:15 a.m. Central Daylight Time, Room E253D

Poster Session 222: Pathogenesis and Therapeutics in Agents of

Bioterrorism

-- Poster: Poster B-2031: Efficacy of Cethromycin Against a Lethal

Inhalation Anthrax Challenge in Rhesus Macaques

Wednesday, September 19, 12:15 p.m. Central Daylight Time, Hall D

Poster Session 176: Macrolides, Ketolides, Bicyclolides and Quinolones

-- Poster E-1633: Assessment of In Vitro Activity of Cethromycin Against

Telithromycin-resistant Strains of Streptococcus pneumoniae

-- Poster E-1632: Assessment of In Vitro Activity of Cethromycin Against

Strains of Streptococcus pneumoniae

-- Poster E-1631: Assessment of In Vitro Activity of Cethromycin Against

Strains of Haemophilus influenzae

-- Poster E1634: Antimicrobial Activity of Cethromycin, a Novel Ketolide,

Tested against a Diverse Collection of Francisella tularensis Strains

Thursday, September 20, 9:00 a.m. Central Daylight Time, Hall D

Poster Session 82: New Drug Pharmacokinetics

-- Poster A-797: Evaluation of the Safety and Pharmacokinetics of

Cethromycin Following Administration of Multiple Doses to Subjects with

Severe Renal Impairment

-- Poster A-796: Evaluation of the Safety and Pharmacokinetics of

Cethromycin Following Administration of Single and Multiple Doses to

Subjects with Mild or Moderate Chronic Hepatic Insufficiency

About ICAAC

The American Society for Microbiology (ASM) is hosting the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which will be held in Chicago, Illinois, September 17 - 20, 2007. More than 12,000 physicians, researchers and other healthcare professionals from around the globe gather each year at ICAAC to foster worldwide solutions to the challenges of infectious diseases.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections.

Forward-Looking Statements

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
10. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):